$1,007.07
−2.52%Price chart
Aug 7Aug 12Aug 17Aug 20Aug 25Aug 28Sep 2Sep 8
ValuationView details →
P/E (Fwd)
120.3x
EV/EBITDA
24.5x
Market Cap
$63.00B
MomentumView details →
1D Return
−2.52%
YTD Return
+19.84%
RSI (14)
55.3
ValuationView details →
P/E (Fwd)
120.3x
EV/EBITDA
24.5x
Market Cap
$63.00B
RSI (14)
55.3
MomentumView details →
1D Return
−2.52%
YTD Return
+19.84%
SummaryUpdated Jun 1, 2026
argenx SE (NASDAQ:ARGX) is a Dutch biotechnology company founded in 2008 and headquartered in Amsterdam, Netherlands. The company went public on NASDAQ in May 2017. argenx has evolved from a research-stage biotechnology company into a commercial-stage biopharmaceutical company with its flagship product VYVGART achieving significant commercial success. The company specializes in developing antibody-based therapies for autoimmune diseases, with a particular focus on conditions affecting the neuromuscular system. argenx has established itself as a leader in targeting the neonatal Fc receptor (FcRn) pathway, a novel mechanism for treating antibody-mediated autoimmune diseases.
Similar companies
Latest newsMore news →
argenx completed its acquisition of Forte Biosciences, Inc., adding the anti-CD122 antibody FB102 to its immunology pipeline.12d agoArgenx announced successful trial results for its biotech product, causing its stock to soar.19d agoargenx announced positive topline results from the Phase 3 ALKIVIA trial of VYVGART Hytrulo (efgartigimod) in autoimmune myositis, meeting its primary endpoint of mean Total Improvement Score at Week 52 in combined IMNM and DM patients (p=0.0011).23d ago